ArticleFrontiers in psychiatry2026
Associations of body mass index and chemotherapy emetogenic risk with sleep disturbance in patients with cancer: a retrospective study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the associations of body mass index (BMI) and chemotherapy emetogenic risk with sleep disturbance in patients with cancer and to explore their multiplicative interaction and joint associations. Methods: This retrospective cross-sectional study analyzed the medical records of 300 patients with cancer who received chemotherapy at Wuhu Second People's Hospital between January 2023 and February 2025. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Multivariable binary logistic regression models were used to examine the associations of BMI and chemotherapy emetogenic risk with sleep disturbance after adjustment for age, sex, cancer type, educational level, and marital status. Multiplicative interaction and joint-association analyses were conducted as exploratory analyses, using patients with normal weight receiving low-to-moderately emetogenic chemotherapy as the reference group in the joint-association analysis. Results: A total of 153 patients (51.0%) had sleep disturbance. After adjustment for age, sex, cancer type, educational level, and marital status, underweight patients (aOR = 2.272, 95% CI: 1.180-4.374, P = 0.014), overweight/obese patients (aOR = 3.171, 95% CI: 1.707-5.893, P < 0.001), and patients receiving highly emetogenic chemotherapy (aOR = 3.009, 95% CI: 1.819-4.977, P < 0.001) had higher odds of sleep disturbance. The overall multiplicative interaction between BMI category and chemotherapy emetogenic risk was statistically significant (P for interaction = 0.008). In the joint-association analysis, underweight patients receiving highly emetogenic chemotherapy had higher odds of sleep disturbance (aOR = 7.373, 95% CI: 2.644-20.555, P < 0.001), while overweight/obese patients receiving highly emetogenic chemotherapy showed the highest observed odds (aOR = 13.794, 95% CI: 4.740-40.139, P < 0.001); 87.2% of patients in this subgroup had sleep disturbance. Conclusions: Abnormal BMI and high chemotherapy emetogenic risk were associated with higher odds of sleep disturbance among patients with cancer. The exploratory interaction and joint-association analyses suggested that patients with abnormal BMI receiving highly emetogenic chemotherapy, particularly those with overweight/obesity, may represent a clinically vulnerable subgroup requiring closer sleep assessment. Given the retrospective cross-sectional design, relatively small subgroup sizes, and wide confidence intervals, these findings should be interpreted as exploratory and do not establish causal relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.